GlassScriptPhysician profile
Candace Trippe
NPI 1295444255
$5,189.22
in general payments reported to CMS, 2019-2025
21 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.94 · 2023: $1,634 · 2024: $2,267 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,170.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,212.37 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $756.19 | 2023-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $485.38 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $463.78 | 2023-2025 | |
| Corium, LLC | $353.18 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $327.64 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $253.76 | 2024-2025 | Auvelity |
| Lundbeck LLC | $223.33 | 2023-2025 | Rexulti, Abilify Maintena |
| Noven Therapeutics, LLC | $217.25 | 2023-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $161.96 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $141.60 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $114.32 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $107.18 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $104.80 | 2023-2025 | Austedo, Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $89.26 | 2024-2025 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $48.16 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $44.95 | 2023 | Trintellix |
| Neos Therapeutics, LP | $32.00 | 2023 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $20.48 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $17.88 | 2023 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $13.75 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Trippe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.